HeartBeam, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All BEATW news ›HeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk Patients
Oct 15, 2026 8:31am EDT Within EXIT-CVD, the HEART-CHECK study will evaluate the HeartBeam System for early detection and triage of cardiac events in high-risk patients recently discharged after an acute coronary syndrome (ACS), a group…
HeartBeam (NASDAQ:BEAT) Upgraded at Wall Street Zen
Posted by Kim Johansen on Oct 13th, 2026 Wall Street Zen upgraded shares of HeartBeam (NASDAQ:BEAT – Free Report) to a sell rating in a research note issued to investors on Saturday morning,Wall Street Zen reports. Get Our Latest Analysis…
HeartBeam director receives 93,750-unit stock grant
HeartBeam, Inc. (NASDAQ: BEAT) develops portable 3D ECG and 12-lead synthesis technologies for arrhythmia assessment and cardiac monitoring outside clinical settings. HeartBeam director receives 93,750-unit stock grant The RSUs and options…
HeartBeam grants Richard Ferrari stock and options
HeartBeam (BEAT) grants Ferrari 90,625 special stock units tied to suspended cash retainers. Stock Titan HeartBeam grants Richard Ferrari stock and options The special RSU award to a director was linked to the suspension of cash retainers…
HeartBeam grants director Jaff 93,750 stock units
A 37,500-unit special award at HeartBeam (BEAT) accompanies suspended July–December 2026 cash retainers. Stock Titan HeartBeam grants director Jaff 93,750 stock units The special award's unvested units vest before a Change in Control if…
HeartBeam grants director Willem Elfrink equity awards
HeartBeam, Inc. (NASDAQ: BEAT) develops portable 3D ECG and 12-lead synthesis technologies for arrhythmia assessment and cardiac monitoring outside clinical settings. HeartBeam grants director Willem Elfrink equity awards The director's…
HeartBeam (BEAT) Stock Soars 62% After FDA Breakthrough Win
HeartBeam (BEAT) stock climbed sharply this week after the company landed a major regulatory win. Shares were up 62% to 71 cents at the time of publication, having surged as much as 90% during the session. The jump came after the U.S. Food…
HeartBeam Receives FDA Breakthrough Device Designation for At-Home Heart Attack Assessment
citybuzz - HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its HeartBeam System as a tool for…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
stocktitan.net7
-
coincentral.com1
-
mugglehead.com1
-
themarketsdaily.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.